GlobeNewswire by notified

Equinor ASA: Meldepliktig handel

Del

Tildeling av aksjer til enkelte primærinnsidere og deres nærstående i Equinor (OSE: EQNR, NYSE: EQNR) i henhold til Equinor’s aksjespareprogram og langtidsinsentivprogram.

Enkelte primærinnsidere, samt deres nærstående, som deltar i Equinor’s aksjespareordning har den 19. mai 2023 fått tildelt aksjer.

Videre har enkelte primærinnsidere som deltar i Equinor’s langtidsinsentivprogram den 19. mai 2023 fått tildelt aksjer til en kurs på NOK 300,94 pr aksje i forbindelse med selskapets langtidsinsentivprogram.

Langtidsinsentivprogrammet er et fast lønnselement som blir beregnet som en andel av deltakernes grunnlønn, og er på 20-30 prosent avhengig av den enkelte deltakerens stilling. Netto årlig beløp investeres i Equinor aksjer. Aksjene er bundet i tre år.

Detaljer om individuelle tildelinger av aksjer til primærinnsidere og deres nærstående er inntatt i vedlegg.

Denne opplysningen er informasjonspliktig etter EU Market Abuse Regulation, jf. verdipapirhandelloven § 3-1, samt verdipapirhandelloven §5-12.


Vedlegg

Hvis du vil se dette innholdet fra www.globenewswire.com, gi ditt samtykke øverst på denne siden.
Hvis du vil se dette innholdet fra ml-eu.globenewswire.com, gi ditt samtykke øverst på denne siden.

Om GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg pressemeldinger fra GlobeNewswire by notified

Registrer deg med din e-postadresse under for å få de nyeste sakene fra GlobeNewswire by notified på e-post fortløpende. Du kan melde deg av når som helst.

Siste pressemeldinger fra GlobeNewswire by notified

Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program16.4.2024 22:10:00 CEST | Press release

Due to the broad diversity in the UV1 Phase II program and the encouraging results from previous UV1 trials, Ultimovacs remain confident in UV1’s potential and are strongly committed to bringing the company across the next important data points: The readout from FOCUS in Q3 2024 and DOVACC results in H1 2025Activity level adjustments and operational prioritization are implemented to sustain the financial runway, including a workforce reduction of approximately 40% The operational adjustment plan extends the anticipated cash runway to the fourth quarter of 2025, through the readout from the Phase II DOVACC trial Oslo, April 16, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces a plan to optimize its business operations to support the continuous advancement of UV1 and long-term business growth. “We remain dedicated to our investigation of the potential impact of UV1 vaccine across several c

ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations16.4.2024 22:05:00 CEST | Press release

ASPIRE-FTD Sites in the EU and U.S. to Use ClearPoint® Navigation Together With SmartFlow® Cannula for Intrathalamic Gene Therapy Administration SOLANA BEACH, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner AviadoBio on treating its first patient in the ASPIRE-FTD Phase 1/2 clinical trial evaluating its investigational gene therapy AVB-101 in people with frontotemporal dementia (FTD) with progranulin (GRN) mutations. “FTD is an important cause of dementia in people under 65 and has a devastating impact on patients and families. The importance of accurately delivering this one-time gene therapy to the thalamus, while minimizing systemic exposure, is the precise use case of ClearPoint’s minimally invasive platform for gene and cell delivery,” stated Jeremy Stigall, Chief Business Officer at ClearPoin

Nokia Corporation: Repurchase of own shares on 16.04.202416.4.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 16 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 16.04.2024 Espoo, Finland – On 16 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL557,6403.17CEUX--BATE--AQEU--TQEX--Total557,6403.17 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of

Questex’s IHIF EMEA 2024 Day 2 is Full of Insightful Discussions and Partnerships16.4.2024 20:06:33 CEST | Press release

LONDON, April 16, 2024 (GLOBE NEWSWIRE) -- Day two of Questex’s International Hospitality Investment Forum EMEA (IHIF EMEA) brought deep insights into macro travel trends, supply and demand, the drivers of profit, how capital is attracted and invested, how global level deals are done and how changing trends influence what owners, brands and operators do with the customer offering. The Capital Talks panel session is one of the most eagerly anticipated spots on the programme. In a discussion moderated by Kenneth Hatton, managing director, head of hotels, Europe at CBRE, IHIF EMEA delegates learned about the underlying trends supporting hospitality investment. Representatives from KSL Capital Partners, Starwood Capital and AXA Investment Managers talked about the finer points of the current hospitality landscape. Josh Cleveland, partner & head of EMEA, real estate, StepStone Group said that hospitality’s “strong inflation hedge” had convinced the firm to invest in the asset class in an in

Markets EQ Announces Titanium: The Next Evolution in AI-Powered Financial Communication16.4.2024 19:02:14 CEST | Press release

New York, NY, April 16, 2024 (GLOBE NEWSWIRE) -- Markets EQ, the first to fuse voice tones with language in a generative AI platform for corporate communications, today unveiled Titanium. Built for the discerning needs of investor relations and financial communications professionals, Titanium offers unparalleled AI security, marking a leap forward in securely navigating pre- and post-earnings calls with advanced AI insights. Titanium is designed to bridge the critical value gaps in financial narratives, enabling users to craft and refine their investor stories with precision. Its unique capabilities ensure that professionals are equipped with the best-in-class linguistic and tonal AI tools, transforming earnings call preparation and analysis into a more strategic and insightful process, saving time on reviews, providing real-time feedback, and securing sensitive information. “At Markets EQ, we recognize the dual imperative of security and intelligence in financial communications. Titan

HiddenA line styled icon from Orion Icon Library.Eye